Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on nets $157.6mm for Ardea Biosciences

Executive Summary

Ardea Biosciences Inc. (working on small-molecule therapeutics for gout, HIV, and cancer) has netted $157.6mm through the follow-on offering of 9.8mm common shares (including the overallotment) at $17 each. Part of the proceeds will support ongoing Phase III trials of the company's lead candidate lesinurad for gout.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies